The intestinal pathogen C. difficile is most commonly found in hospitals and is often acquired by older people and people with weakened immune systems. In Western countries, infections with so-called hypervirulent strains of C. difficile are rapidly increasing and are much more dangerous and more difficult to treat. The pathology of C. difficile infections is primarily triggered by two toxins released by the pathogen, which then damage the intestinal epithelium. Particularly dangerous hypervirulent strains produce a third toxin, C. difficile transferase (CDT). This CDT toxin modifies the cytoskeleton, causing the host cells to collapse and die. Aktories and Papatheodorou identified the surface protein LSR (lipolysis-stimulated lipoprotein receptor) as the receptor for the CDT toxin already in 2011. It is through the LSR that CDT enters the host cell.
Papatheodorou, Aktories and their team of researchers have now identified the regions in the CDT toxin and the LSR receptor that interact with one another. In order to achieve this, the scientists genetically designed truncations of the toxin and the LSR receptor as well as cells without LSR. They then tested whether or not the CDT toxin could bind to its receptor and be absorbed in the cell. They discovered that the parts of the toxin that interact with the receptor are much smaller than previously believed. All that is necessary for toxin absorption is the part of the receptor outside of the cell. “In the future, it should be possible to block these areas in the toxin and receptor in order to prevent the toxin from entering the host cell,” Papatheodorou explained.
Papatheodorou and Aktories are researchers at the Institute of Experimental and Clinical Pharmacology and Toxicology at the University of Freiburg. Aktories is also a member of the cluster of excellence BIOSS Centre for Biological Signalling Studies at the University of Freiburg.
To read the article in its entirety click on the link below: